Teva and Par Cheered By Depression Generics OKs
Posted on: Monday, 3 July 2006, 12:00 CDT
Two new depression drug generics are set to hit the US market following the FDA's approval of both Teva's Zoloft generic and Par Pharmaceutical's copycat version of GlaxoSmithKline's Parnate.
Beginning with Teva, the Israeli generics giant has received final FDA approval for its abbreviated new drug application (ANDA) to market a generic version of Pfizer's Zoloft (sertraline) tablets, 25mg, 50mg, and 100mg.
Teva's AB-rated sertraline tablets are indicated for the treatment of major depressive disorder.
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity, which will start upon the initiation of a commercial launch. Teva is now in receipt of final labeling and is making preparations to launch this product before the end of July.
Par's approval, meanwhile, relates to an ANDA submitted by its wholly-owned subsidiary, Kali Laboratories, for tranylcypromine sulfate tablets, 10mg. Tranylcypromine is the generic version of GlaxoSmithKline's Parnate and is used for the treatment of depression.
Source: Datamonitor
Related Articles
- FDA Approves Generic Metronidazole
- FDA Approves Generic Version of Zoloft
- Teva, Ranbaxy Get OK for Generic Zocor
- USAN and WHO Approve Generic Name Bremelanotide for PT-141, First in a New Class of Experimental Treatments for Sexual Dysfunction
- U.S. Drug Agency Preliminarily Approves Generic Version of AIDS Medicine
- US FDA approves generic AIDS drug for use overseas
- Mutual Pharmaceutical Announces ANDA Approval for Folic Acid 1mg Tablets
- Mutual Pharmaceutical Announces ANDA Approval for Butalbital 50mg/Acetaminophen 325mg/Caffeine 40mg Tablets
- FDA Approves Generic AIDs Drug Combo
- FDA Approves Generic Versions of Oxycontin
 |
 |
User Comments (0)
RSS Feeds